L-744832

L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer^[1][2]. In Vitro:L-744832 (0.1-50 μM, 24-72 h) shows significant differences in sensitivity in Panc-1, Capan-2, BxPC-3, AsPC-1 and CFPAC-1 cells with IC₅₀s of 1.3, 2.1, 12.3, 14.3 and > 50 μM^[1].
L-744832 (0.1-50 μM, 72 h) arrest the sensitive cell lines (Panc-1, Capan-2, BxPC-3 and AsPC-1) in the G2/M phase of the cell cycle and the arrest occurs during the mitotic entry stage downstream of the G2/M checkpoint^[1].
L-744832 (10 μM, 24-72 h) induces above five types of cell apoptosis, and the combination of radiotherapy can significantly increase the apoptosis rate of MIA PaCa-2 cells, while this effect is not observed in BxPC-3 cells^[1][2].
L-744832 (0.1-10 μM) with ionizing radiation results in enhanced cytotoxicity in human pancreatic cancer cells^[1].
L-744832 (5-10 μM) effectively inhibits the farnesylation of H-Ras and N-Ras and MIA PaCa-2 cells are more sensitive than BxPC-3 cells^[2].
L-744832 (5-10 μM, 3-6 h) restores the expression of TGF-β type II receptor (RII) through regulating DNMT1, thereby re-establishing the tumor-suppressing function of TGF-β^[2].